Mozavaptan

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Mozavaptan
Mozavaptan structure.svg
Systematic (IUPAC) name
N-[4-(5-Dimethylamino-2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)phenyl]-2-methylbenzamide
Clinical data
Legal status Prescription only
Routes Oral
Identifiers
CAS number 137975-06-5 N
ATC code None
PubChem CID 119369
ChemSpider 106618 YesY
UNII 17OJ42922Y YesY
ChEMBL CHEMBL420762 YesY
Chemical data
Formula C27H29N3O2 
Mol. mass 427.53 g/mol
 N (what is this?)  (verify)

Mozavaptan (INN) is a vasopressin receptor antagonist marketed by Otsuka. In Japan, it was approved in October 2006 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH) due to ADH producing tumors.

References[edit]